To the Editor — Human organoids hold tremendous potential for biomedical applications1,2,3 (Fig. 1a,b). These three-dimensional structures of cultured cells recapitulate important aspects of in vivo organ development and biological function. They provide tractable in vitro models of human physiology and pathology, thereby enabling interventional studies that are difficult or impossible to conduct in human subjects. For example, organoids allow genetic and pharmacological manipulation in a complex cellular context that reflects human biology, and they enable investigations of the early stages of organ development and disease onset. Human organoids complement (and may eventually replace) animal models in many areas of preclinical drug development. Moreover, they provide patient-specific ‘avatars’ for drug development and precision therapies, including treatments for cancer, rare genetic diseases (such as cystic fibrosis) and complex multifactorial disorders (such as epilepsy). Finally, they promise to contribute to regenerative medicine, with the goal of producing functional biological structures that can be transplanted into patients.
To realize the full potential of human organoids, key challenges need to be addressed (Fig. 1c). Most immediately, we need better characterization and validation of organoids as faithful models of human biology. This will require assays for informative high-throughput profiling as well as the definition of quality standards for cell composition, cellular differentiation, cell states and responses to stimuli. A future catalog of well-characterized human organoids should include extensive replication, to quantify technical and biological sources of variation. Moreover, inclusion of genetically diverse sample donors will help to assess interindividual variation in the human population.
Current organoid protocols, while useful for many applications, have relevant technical and conceptual limitations. For example, organoids may not faithfully represent the diversity of cell types in primary tissue (including non-parenchymal cells such as immune cells and stroma), and they are limited in their ability to account for the effects that environmental exposures and organismal aging have on human organs in vivo. It will be important to develop robust protocols that yield organoids with adequate tissue organization, differentiated cells, vascularization, immune cell infiltration and, for some organs (for example, skin and intestine), even a microbiome. Moreover, we are still learning how to use organoids most effectively for discovering biology (for example, through genetic and pharmacological perturbations) and how to exploit them for drug development and personalized medicine.
Single-cell sequencing and spatial profiling have a key role in addressing these issues (Fig. 1d). Comprehensive molecular maps of organoids and organoid development can reveal cell states and transcription regulatory programs in unprecedented detail, and comparisons to corresponding human tissues in vivo provide powerful new ways of evaluating organoids. Single-cell epigenome and transcriptome profiling yields a quantitative, high-dimensional assessment of cell composition and cell states within organoids. Spatial profiling assays characterize tissue organization and three-dimensional architecture. These methods also enhance organoid quality control (for example, identifying outliers, missing cell types or aberrant gene regulation), and they can provide reference atlases for disease-centric studies. Furthermore, comparative molecular profiling of organoids and matched ex vivo tissue samples can guide the development of new and improved organoid protocols, for example, by identifying missing cell populations or bottlenecks of cellular differentiation in organoids. Finally, single-cell technologies provide a powerful and scalable readout for functional experiments and for genetic or pharmacological perturbations that are tested in human organoids.
To demonstrate the feasibility and utility of combining human organoids with single-cell technology, we have launched an Organoid Cell Atlas pilot project, as a ‘Biological Network’ within the Human Cell Atlas (HCA)4,5,6, focusing on the single-cell characterization of organoids and complex in vitro systems (https://www.humancellatlas.org/coordinators). The Organoid Cell Atlas will facilitate the production, quality control, dissemination and utilization of single-cell and spatial genomics data for human organoids, and it will link such datasets to the comprehensive profiles of primary tissues that are being generated within the HCA. A first step toward establishing the Organoid Cell Atlas has recently been funded by the European Union Horizon 2020 call for “Pilot actions to build the foundations of a human cell atlas” with the ‘HCA|Organoid’ project (https://hca-organoid.eu).
The Organoid Cell Atlas within the HCA
The Organoid Cell Atlas will be a cornerstone of the HCA. It is central to the HCA’s mission of creating comprehensive reference maps of all human cells as a basis for understanding human health and for diagnosing, monitoring and treating disease. Like the Human Genome Project7, the HCA is expected to have substantial biomedical impact, most notably in areas such as precision medicine and regenerative biology. Human organoids will be of great importance in the HCA6, as they complement the profiling of primary tissue samples with a readily perturbed model for functional studies while also benefitting from the profiling of human tissues to which they can be compared.
Some of the first applications of single-cell profiling in organoids included single-cell RNA-seq analysis of the cellular composition of mouse intestinal organoids8 and human brain organoids9. Other pioneering studies uncovered complex cellular networks10 and used single-cell profiles to improve organoid derivation protocols11. These initial reports identified striking parallels among organoid development, human primary tissue and in vivo organogenesis, which reinforces the potential of organoids for dissecting human biology in vitro.
To exploit synergies between single-cell profiling and organoid technologies, the Organoid Cell Atlas has been initiated in close coordination with the HCA leadership, following the example of other specialized atlases such as the Pediatric Cell Atlas12 and the Human Tumor Cell Atlas Network13. The Organoid Cell Atlas is an open, collaborative network that pursues four complementary directions: first, encourage and standardize single-cell profiling of human organoids; second, facilitate access to single-cell organoid data (and informative metadata) via HCA data infrastructure; third, establish computational methods and tools for connecting organoid profiles with primary tissue data; and fourth, put organoids into their biological context using HCA profiles of their in vivo counterparts. The envisioned data integration will be driven by an interactive, openly accessible, web-based computational platform called the Organoid Cell Atlas Portal, which will build on and extend the existing HCA data infrastructure.
An initial version of the Organoid Cell Atlas
The European Union Horizon 2020 (EU H2020) HCA|Organoid project enables us to establish a first version of the Organoid Cell Atlas over the coming years, which may act as a nucleus for a broader, collaborative, global initiative. In this pilot project, we are generating single-cell transcriptome profiles, epigenome maps and detailed imaging data in a selection of human organoids. For two organs, colon and brain, we will derive and characterize organoids from 100 whole-genome-sequenced individuals each, to capture normal population variation and to establish a reference for disease-centric studies (Fig. 2a,b). User-friendly access to the single-cell data for organoids and comparisons between organoid profiles and single-cell data for human primary tissues will be available on the Organoid Cell Atlas Portal, which is being developed in parallel with the data generation.
We selected colon and brain organoids as the two focus areas of the HCA|Organoid project for three reasons: first, colon and brain were among the first organs for which organoids were demonstrated, so relatively mature protocols are now available; second, colon organoids are derived from adult stem cells in primary ex vivo samples while brain organoids are derived from pluripotent cells, thus spanning the two main sources of organoid derivation; third, colon and brain organoids have already been used for disease-centric studies, and single-cell characterization of these organoids for a large number of individuals will facilitate biomedical applications. Beyond the initial focus on colon and brain organoids, the HCA|Organoid project is designed in such a way that most of the data infrastructure is generic and applicable to other types of human organoids. We actively seek collaboration with other projects that pursue systematic single-cell profiling in other types of human organoids to explore the possibility of interconnection or integration with the Organoid Cell Atlas.
The Organoid Cell Atlas Portal is a central aim of the EU H2020 HCA|Organoid project. It will provide computational infrastructure and a web-based front end that make single-cell data for human organoids easy to access and analyze. This effort will build upon the existing Data Coordination Platform infrastructure of the HCA (https://data.humancellatlas.org) for data submission, processing, annotation and retrieval. Key features that are specific to organoids will include the interactive exploration of human organoid data, data-driven selection of organoids for functional experiments, and comparison of disease-specific organoids against reference collections of normal organoids.
The Organoid Cell Atlas Portal will also provide interactive mappings between single-cell profiles of human organoids and the corresponding primary tissues available within the HCA, using algorithms that enable cell–cell alignments between these datasets. This functionality will facilitate and encourage the use of organoids as a model for detailed biological experiments, including the identification of target genes for mechanistic research and drug development. The mapping and data integration will also allow exploration of normal variation between individuals (for example, due to common genetic differences) in an interactive manner, leveraging organoids as a model for the corresponding variation in primary tissues. Finally, the cell–cell alignments will facilitate the analysis and interpretation of perturbations in human organoids in the context of the corresponding primary tissues.
We will pursue several complementary strategies to ensure that the data in the Organoid Cell Atlas will be of the highest possible quality and reproducibility. First, we will invest in standardization and validation of experimental workflows for organoid derivation — for example, by comparing alternative protocols and by assessing the relative effect of technical and biological factors on the single-cell profiles of colon and brain organoids. Second, we will contribute to HCA efforts to establish community standards and software infrastructure for data processing and data annotation — for example, by ensuring compatibility with the specific metadata structure for organoids. Third, we will develop and validate computational methods for the flexible alignment and comparison of cells between organoids and corresponding primary tissue. Finally, we will implement interactive visualization tools that enable user-friendly quality control and exploratory analysis of single-cell organoid datasets contributed to the Organoid Cell Atlas.
To maximize the utility and impact of the EU H2020 HCA|Organoid project for the broader scientific community, single-cell profiles will be made public as rapidly as possible, in concordance with the HCA’s strong commitment to data sharing, local ethical regulations and the European data protection law (GDPR). Newly established organoids will be provided as a ‘living biobank’ via Hubrecht Organoid Technology14 (colon) or as a set of precise protocols for derivation from biobanked induced pluripotent stem cell lines (brain). Furthermore, we will evaluate and explore the practical utility of the Organoid Cell Atlas in a series of disease-centric pilot studies, pursuing CRISPR screening with single-cell transcriptome readout (CROP-seq)15 and disease modeling of genetic epilepsy using brain organoids selected from the Organoid Cell Atlas. Finally, we are committed to developing the Organoid Cell Atlas Portal into a public, sustainable and widely used infrastructure for finding, accessing, analyzing and interpreting single-cell data from human organoids.
With recent technological advances, human beings are becoming the leading ‘model organism’ for the discovery of important new biology and the development of therapeutic strategies. The HCA is catalyzing this paradigm shift by establishing reference maps of all human cells, for the first time providing a detailed molecular picture of the human body. In vitro models such as organoids will complement these efforts by enabling researchers to functionally dissect and systematically perturb human biological systems. In the context of the HCA, the EU H2020 HCA|Organoid project is committed to establishing a practically useful and readily extensible initial version of the Organoid Cell Atlas within two years, while extensive further work will be needed to maximize the impact of the Organoid Cell Atlas for basic biology and biomedical applications. Beyond the initial focus on colon and brain, the Organoid Cell Atlas will incorporate datasets from other organoids and organ systems through the HCA data infrastructure and in collaboration with the other HCA Biological Networks.
The mission of the Organoid Cell Atlas is to advance biomedical discovery and the development of regenerative therapies by supporting and accelerating disease-centric research in areas such as rare genetic diseases, complex multifactorial diseases and precision oncology. This overarching goal can be achieved by creating an open and inclusive research environment that facilitates collaboration among a broad range of interested researchers, bridging communities and integrating expertise in organoids and single-cell technology.
Clevers, H. Cell 165, 1586–1597 (2016).
Lancaster, M. A. & Knoblich, J. A. Science 345, 1247125 (2014).
Rossi, G., Manfrin, A. & Lutolf, M. P. Nat. Rev. Genet. 19, 671–687 (2018).
Regev, A. et al. eLife 6, e27041 (2017).
Rozenblatt-Rosen, O., Stubbington, M. J. T., Regev, A. & Teichmann, S. A. Nature 550, 451–453 (2017).
Regev, A. et al. The Human Cell Atlas white paper. Preprint at https://arxiv.org/abs/1810.05192 (2017).
Lander, E. S. Nature 470, 187–197 (2011).
Grün, D. et al. Nature 525, 251–255 (2015).
Camp, J. G. et al. Proc. Natl Acad. Sci. USA 112, 15672–15677 (2015).
Quadrato, G. et al. Nature 545, 48–53 (2017).
Wu, H. et al. Cell Stem Cell 23, 869–881.e868 (2018).
Taylor, D. M. et al. Dev. Cell 49, 10–29 (2019).
Rozenblatt-Rosen, O. et al. Cell 181, 236–249 (2020).
van de Wetering, M. et al. Cell 161, 933–945 (2015).
Datlinger, P. et al. Nat. Methods 14, 297–301 (2017).
We thank S. Ladstätter for comments on the manuscript and B. R. Malhotra for assistance with figure preparation. The HCA|Organoid project is funded by the European Union’s Horizon 2020 research and innovation programme (grant agreement no. 874769, coordinator: C.B.). C.B. is supported by an ERC Starting Grant (European Union’s Horizon 2020 research and innovation programme, grant agreement no. 679146). A.R. is supported by the Klarman Cell Observatory and the Howard Hughes Medical Institute. J.A.K. is supported by the Austrian Federal Ministry of Education, Science and Research; the Austrian Academy of Sciences; the Austrian Research Fund (FWF SFB F78 Stem Cell, F 7803-B); and the European Research Council (European Union’s Horizon 2020 research and innovation programme, grant agreements no. 695642 and 693184). This publication is part of the Human Cell Atlas (https://www.humancellatlas.org/publications).
C.B. is cofounder and scientific advisory board member of Aelian Biotechnology and an inventor on patent applications relating to genome technology. H.C. is an inventor on patents held by the Royal Netherlands Academy of Arts and Sciences that cover organoid technology (full disclosure: https://www.uu.nl/staff/JCClevers/Additional%20functions). J.A.K. is an inventor on several patents involving pluripotent stem cell–based organoid technology, and cofounder and scientific advisory board member of a:head bio. A.R. is cofounder of Celsius Therapeutics; equity holder of Imunitas; scientific advisory board member of Syros Pharmaceuticals, Thermo Fisher Scientific, Asimov and NeoGene Therapeutics; and co-inventor on patent applications filed by the Broad Institute relating to single-cell genomics. S.A.T. consults for Genentech and Roche, and serves on the scientific advisory board for Biogen, Foresite Labs and GlaxoSmithKline. R.G.J.V. is an inventor on a patent involving adult stem cell–based organoid technology and a full-time employee of the Foundation Hubrecht Organoid Technology (HUB), which holds an exclusive license on organoid technology patents.
Editorial note: This article has been peer reviewed.
About this article
Cite this article
Bock, C., Boutros, M., Camp, J.G. et al. The Organoid Cell Atlas. Nat Biotechnol 39, 13–17 (2021). https://doi.org/10.1038/s41587-020-00762-x